Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 0.7% – Should You Buy?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) traded up 0.7% on Wednesday. The stock traded as high as $1.3849 and last traded at $1.37. 58,591 shares were traded during trading, a decline of 33% from the average daily volume of 87,142 shares. The stock had previously closed at $1.36.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Price Performance

The firm has a market cap of $7.56 million, a P/E ratio of -0.51 and a beta of -2.02. The company’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $2.09.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). Equities research analysts predict that Acurx Pharmaceuticals, Inc. will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.